Recent developments in AI have provided assisting tools to support pathologists’ diagnoses. However, it remains challenging to incorporate such tools into pathologists’ practice; one main concern is AI’s insufficient workflow integration with medical decisions. We observed pathologists’ examination and discovered that the main hindering factor to integrate AI is its incompatibility with pathologists’ workflow. To bridge the gap between pathologists and AI, we developed a human-AI collaborative diagnosis tool — xPath — that shares a similar examination process to that of pathologists, which can improve AI’s integration into their routine examination. The viability of xPath  is confirmed by a technical evaluation and work sessions with twelve medical professionals in pathology. This work identifies and addresses the challenge of incorporating AI models into pathology, which can offer first-hand knowledge about how HCI researchers can work with medical professionals side-by-side to bring technological advances to medical tasks towards practical applications.

No abstract

No abstract

Background: It has been less than two years since the advent of the COVID-19 pandemic, and there are plenty of publications describing the clinical and pathological features of this severe infectious disease, damaging not only lung but also other vital organs. However, the pathologic findings of long-term complications post virus infection have rarely been described. Case presentation: We are reporting three autopsy cases from patients who had COVID-19 one to six months before death. The patients were all SARS-CoV-2 negative at admission but expired shortly. At autopsy, the first patient showed subacute diffuse myocardial ischemic injury with microthrombi in pericardial small vessels, whereas the second patient showed catastrophic acute and subacute pulmonary infarctions with hemothorax leading to respiratory failure. The third patient showed subacute severe cerebral infarcts in the left middle cerebral artery region. Conclusions: Our findings suggest the hypercoagulopathy and subsequent vital organ damage may persist beyond the active phase of SARS-CoV-2 infection. It is essential to evaluate and continue monitoring the COVID-19 patients after recovery, so as to identify the ones with vital organ injury in a timely manner and to take the steps to prevent severe consequence of COVID-19 complications.